Abstract

To the Editor, Guo et al. [1] conducted a meta-analysis to evaluate the role of cytovillin expression on the overall survival rate by calculating the pooled risk ratio (RR) with the corresponding 95 % confidence interval (95 % CI). They concluded that the cytovillin expression is obviously associated with lower overall survival rate in osteosarcoma patients, and it is an effective biomarker of prognosis. Before accepting their conclusions, we would like to express some concerns in relation to their meta-analysis. To begin with, the investigators did not provide us with the flow diagram of the study selection procedure. To make us read the meta-analysis better, the investigators should have provided one. Furthermore, we suggest that the investigators should evaluate the methodological quality of the selected studies, which could avoid the potential bias in the meta-analysis. Each included paper could be independently assessed by two investigators using a standardized electronic form of predefined criteria. Meanwhile, the investigators could describe how to evaluate the quality of all studies in the meta-analysis. In addition, the investigators included eight studies including 415 osteosarcoma patients. However, the investigators did not provide us any characteristics of these eligible studies. For us to read the meta-analysis well, we suggest that the investigators should provide us with the characteristics, such as patient source, histo-subtype (Osteo%), stage of osteosarcoma, RR estimation, and survival results. Eventually, in the “Results” section, the investigators used a forest plot to show the effect of cytovillin expression on the overall survival rate. However, we are wondering what does the overall survival rate, 2-year survival, or 5-year survival mean? Meanwhile, the investigators did not evaluate the effect of cytovillin expression on clinical stage and the neoplasm metastasis. In our opinion, these should be added in the “Results” section to make a better meta-analysis. In a word, more studies with large sample size are needed to provide a more comprehensive evaluation of the prognostic role of cytovillin expression in patients with osteosarcoma.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.